Medical Doctor Program year 2024 Reported 2020–2024 Source: CMS Open Payments, 2026 publication

Matthew Elliott

Allergy & Immunology Jackson, MS Medical Doctor

NPI 1356873723 CMS profile 8800943

2500 N State St, Jackson, MS 39216

Open in the dashboard

General payments

$862

30 records reported · program years 2020–2024

Research payments

$0

Paid to them · None reported · program years 2020–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Matthew Elliott of Jackson, MS is reported in the CMS Open Payments database as having received $862 across 30 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 35th percentile of Allergy & Immunology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $133 1
2022 General $252 10
2021 General $428 16
2020 General $49 3

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Matthew Elliott
  • Allergy & Immunology median
  • Middle half of Allergy & Immunology
  • National median

In program year 2025, general payments to Matthew Elliott were reported at $0. Among 336 Allergy & Immunology profiles paid that year, the median was $682 and the middle half received between $143 and $2,317.

Show as a table
Year Matthew Elliott Allergy & Immunology median Middle half National median
2019 $0 $378 $115–$1,178 $163
2020 $49 $303 $75–$1,581 $114
2021 $428 $407 $122–$1,475 $132
2022 $252 $357 $120–$1,340 $149
2023 $0 $445 $124–$1,536 $160
2024 $133 $541 $129–$1,763 $164
2025 $0 $682 $143–$2,317 $169

Breakdown

Who paid General payments · program years 2020–2024
  1. AstraZeneca Pharmaceuticals LP $304 10 payments
  2. Regeneron Healthcare Solutions, Inc. $168 2 payments
  3. GlaxoSmithKline, LLC. $136 8 payments
  4. CSL Behring $70 3 payments
  5. Blueprint Medicines Corporation $62 1 payment
  6. AbbVie, Inc. $42 2 payments
  7. Aimmune Therapeutics, Inc. $24 1 payment
  8. Salix Pharmaceuticals, a division of Bausch Health US, LLC $23 1 payment
  9. Amgen Inc. $19 1 payment
  10. Novo Nordisk Inc $13 1 payment

Every payment, record by record

What the payments were for General payments · program years 2020–2024
  1. Food and Beverage $862 30 payments
Products named General payments · program years 2020–2024
  1. DUPIXENT $168 2 payments
  2. FASENRA $109 8 payments
  3. TRELEGY ELLIPTA $106 6 payments
  4. Hizentra $70 3 payments
  5. AYVAKIT $62 1 payment
  6. TEZSPIRE $61 1 payment
  7. CREON $42 2 payments
  8. PALFORZIA $24 1 payment
  9. XIFAXAN $23 1 payment
  10. NUCALA $16 1 payment
  11. Other $41 3 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 15 drugs

Part D claims

435

Median for Allergy/ Immunology: 449

Drug cost

$191,152

Median for Allergy/ Immunology: $169,700

Branded share of claims

37.2%

Median for Allergy/ Immunology: 37.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Dupixent Pen Dupilumab Brand 24 $89,266
Xolair Omalizumab Brand 26 $61,476
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 23 $19,473
Symbicort Budesonide/Formoterol Fumarate Brand 16 $6,577
Fluticasone-Salmeterol Fluticasone Propion/Salmeterol Brand 13 $2,942
Azelastine Hcl Generic 71 $2,753
Epinephrine Generic 13 $2,565
Ipratropium Bromide Generic 39 $1,506
Albuterol Sulfate Hfa Albuterol Sulfate Brand 37 $1,170
Fluticasone Propionate Generic 62 $920

The 10 drugs with the highest cost, of 15 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,579 Part D prescribers listed as Allergy/ Immunology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 33 billing codes

Paid by Medicare

$21,152

Medicare's payments for the services billed

Medicare patients

141

Average age 68

Services billed

435

89 women, 52 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 54%
Diabetes 46%
Chronic kidney disease 34%
Ischemic heart disease 26%
Depression 24%
Heart failure 21%
COPD 18%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

30 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Allergy & Immunology in Mississippi

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record